Nystatin prophylaxis in immunocompromised children.

Abstract

In conclusion, the use of nystatin for fungal prophylaxis in hematology/oncology/bone marrow transplantation patients appears to convey little or no benefit over no therapy. Nystatin treatment significantly reduced the frequency of multiple-site colonization and of persistently positive oropharyngeal cultures, but was not able to prevent the occurrence of disseminated fungal infections. Other antifungal agents (e.g., ketoconazole, fluconazole, itraconazole, oral or intravenous amphotericin B) may be of benefit. Studies comparing nystatin with other agents are available in the literature but are beyond the scope of this review.

• Authors: T L Taylor
• Journal: The Annals of pharmacotherapy (Ann Pharmacother) Vol. 30 Issue 5 Pg. 534-5 (May 1996) ISSN: 1060-0280 [Print] United States
• PMID: 8740337 (Publication Type: Journal Article, Review)

Chemical References

• Antifungal Agents
• Nystatin

Topics

• Agranulocytosis (complications)
• Antifungal Agents (therapeutic use)
• Bone Marrow Transplantation (adverse effects)
• Candidiasis (etiology, prevention & control)
• Child
• Humans
• Immunocompromised Host
• Leukemia (complications)
• Nystatin (therapeutic use)